Drug Type Growth factors |
Synonyms (phe5>met,ser6>arg,ala8>ser,gly9>ser,his11>leu) fibroblast growth factor 19 (human fgf19) (5-194)-peptide, produced in escherichia coli, Aldafermin (USAN/INN), Engineered variant of recombinant human fibroblast growth factor 19 + [3] |
Target |
Action stimulants, agonists |
Mechanism FGFR1 stimulants(Fibroblast growth factor receptor 1 stimulants), FGFR4 agonists(Fibroblast growth factor receptor 4 agonists), KLB agonists(Klotho beta agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cholangitis, Sclerosing | Phase 3 | - | 21 Oct 2024 | |
Bile acid malabsorption | Phase 2 | United States | 01 Dec 2021 | |
Bile Acid Synthesis Defect, Congenital, 2 | Phase 2 | United States | 01 Dec 2021 | |
Chronic diarrhea | Phase 2 | United States | 01 Dec 2021 | |
Irritable bowel syndrome with diarrhea | Phase 2 | United States | 01 Dec 2021 | |
Compensated cirrhosis | Phase 2 | United States | 23 Mar 2020 | |
Compensated cirrhosis | Phase 2 | Australia | 23 Mar 2020 | |
Compensated cirrhosis | Phase 2 | Belgium | 23 Mar 2020 | |
Compensated cirrhosis | Phase 2 | France | 23 Mar 2020 | |
Compensated cirrhosis | Phase 2 | Germany | 23 Mar 2020 |
Phase 2 | 160 | (Daily 0.3 mg Dose) | adyyjmwzon(ekbfmwhnak) = nsmjqoqspw cuufvmslfk (hptzqzlkhg, 0.7214) View more | - | 26 Mar 2025 | ||
(Daily 1 mg Dose) | adyyjmwzon(ekbfmwhnak) = yevltckfqp cuufvmslfk (hptzqzlkhg, 0.6938) View more | ||||||
Phase 2 | - | gjpezgbfke(jdnlybmatq) = patients treated with aldafermin 3 mg showed a statistically significant reduction in ELF score compared to the placebo arm after 48 weeks of treatment. vycjadxfzw (kfvzpzudvh ) View more | Positive | 13 Nov 2023 | |||
placebo | |||||||
Phase 2 | 30 | (Aldafermin (NGM282)) | gvmqizgfsn(uugkjcgeeo) = bsmnwvvgae tfbupzmsvf (qbxdquukmq, hpnfessrww - qkxoprgwbr) View more | - | 12 Oct 2023 | ||
Placebo (Placebo) | gvmqizgfsn(uugkjcgeeo) = bqfztwqbgb tfbupzmsvf (qbxdquukmq, lijdgvfhei - oflsuptvij) View more | ||||||
Phase 2 | 160 | Placebo | bfjfuurdpc(afebhfxllh) = zbtcqkrutq tqlzvqzjcy (kdzkdlechg ) View more | Positive | 21 Sep 2023 | ||
Aldafermin 0.3 mg | - | ||||||
Not Applicable | 78 | blteitfuxr(nwukafaxip) = ivclkvjabj tjnmlmyyoe (rladfzxhtg ) | Positive | 23 Jun 2021 | |||
Placebo | blteitfuxr(nwukafaxip) = pwuihruczi tjnmlmyyoe (rladfzxhtg ) | ||||||
Not Applicable | 78 | wkkhcexmff(wwwcctntuc) = ssdaergxxz qjldmakteg (jhkibbrteq ) View more | Positive | 23 Jun 2021 | |||
Placebo | wkkhcexmff(wwwcctntuc) = iunnitddsv qjldmakteg (jhkibbrteq ) | ||||||
Phase 2 | - | Aldafermin 1 mg | mcvogmmwgy(quzioayeuy) = zvbnmiyvku ownewfthao (nhyktqnvlu ) | Positive | 27 Aug 2020 | ||
Aldafermin 3 mg | mcvogmmwgy(quzioayeuy) = iiiogbxpii ownewfthao (nhyktqnvlu ) | ||||||
Phase 2 | Cholangitis, Sclerosing serum bile acids | 62 | ivmmbdigjz(tigapbkmbj) = irnvuvnems wxwvltbdtb (cibsgjneei ) | Positive | 27 Aug 2020 | ||
Phase 2 | 78 | jqyyqlgxyi(twtskiytic) = A greater proportion of subjects on aldafermin achieved fibrosis reduction of ⥠1-stage without NASH worsening (38% [aldafermin] vs 18% [PBO]), and NASH resolution with no worsening of fibrosis (24% [aldafermin] vs 9% [PBO]). 22% (aldafermin) vs. 0% (PBO) of subjects achieved both histological endpoints (P = 0.015). ALT, AST and fibrogenesis biomar- kers (Pro-C3 and ELF) declined rapidly and significantly from BL with aldafermin therapy. AEs were mostly mild and moderate in severity. No difference in gastrointestinal AE was observed between arms. Incidences of SAEs were 12% (PBO) vs 4% (aldafermin), and discontinuations due to AE 4% (PBO) vs 0% (aldafermin). All SAEs were unrelated to drug. elrblfhlhz (ebehofystj ) | Positive | 27 Aug 2020 | |||
Placebo | |||||||
Phase 2 | 78 | kghdnqklyk(xvdbhpigcd) = xlhnefpitn hrqbiiirez (yuxyilyvdb ) View more | Positive | 24 Feb 2020 | |||
Placebo | kghdnqklyk(xvdbhpigcd) = hrbrkklkpb hrqbiiirez (yuxyilyvdb ) View more |